Jyong Biotech (NASDAQ:MENS) Issues Quarterly Earnings Results

Jyong Biotech (NASDAQ:MENS) released its earnings results on Friday. The company reported ($0.02) earnings per share (EPS) for the quarter, FiscalAI reports.

Jyong Biotech Trading Down 3.4%

MENS traded down $0.07 during trading on Friday, reaching $2.01. 55,197 shares of the company traded hands, compared to its average volume of 68,867. Jyong Biotech has a 12-month low of $1.43 and a 12-month high of $67.00. The firm has a fifty day simple moving average of $2.21 and a 200 day simple moving average of $10.63.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Jyong Biotech in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has an average rating of “Sell”.

Institutional Investors Weigh In On Jyong Biotech

Institutional investors have recently added to or reduced their stakes in the stock. Millennium Management LLC purchased a new stake in Jyong Biotech during the 3rd quarter valued at approximately $512,000. Jane Street Group LLC purchased a new stake in Jyong Biotech during the 4th quarter valued at approximately $275,000. Geode Capital Management LLC grew its holdings in Jyong Biotech by 19.6% during the 4th quarter. Geode Capital Management LLC now owns 64,382 shares of the company’s stock valued at $254,000 after buying an additional 10,538 shares in the last quarter. BNP Paribas Financial Markets purchased a new stake in Jyong Biotech during the 3rd quarter valued at approximately $67,000. Finally, Man Group plc purchased a new stake in Jyong Biotech during the 4th quarter valued at approximately $56,000.

Jyong Biotech Company Profile

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers’ health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.